BACKGROUND: There is evidence that IL-16, a cytokine that induces chemotactic responses in CD4(+) T cells, eosinophils, and dendritic cells, plays an important role during different types of cutaneous inflammatory responses, including allergic contact dermatitis (ACD) and atopic dermatitis (AD). OBJECTIVES: We sought to test for association between a promoter polymorphism in the IL16 gene (T to C transition at position -295) and ACD and AD, respectively. METHODS: IL16 -295 genotypes were determined in samples from 2 separate case-control studies with white individuals. The first study included healthy individuals (n = 310) and patients with ACD (n = 86). These patients were polysensitized as defined by a contact sensitization to para-substituted aryl compounds and at least one other structurally unrelated allergen. The second study comprised healthy subjects (n = 214) and patients with AD (n = 94). RESULTS: IL16 -295 genotypes were differently distributed among polysensitized and healthy control subjects (P =.0021). In particular, the IL16 -295*C/C genotype was overrepresented among polysensitized individuals (7.0% vs 1.0% in the control group; odds ratio, 7.68; 95% CI, 1.59-48.12). In contrast, there was no evidence for an association between the IL16 -295 polymorphism and AD. CONCLUSION: The IL16 -295 promoter polymorphism might influence susceptibility to contact allergy.
BACKGROUND: There is evidence that IL-16, a cytokine that induces chemotactic responses in CD4(+) T cells, eosinophils, and dendritic cells, plays an important role during different types of cutaneous inflammatory responses, including allergic contact dermatitis (ACD) and atopic dermatitis (AD). OBJECTIVES: We sought to test for association between a promoter polymorphism in the IL16 gene (T to C transition at position -295) and ACD and AD, respectively. METHODS:IL16 -295 genotypes were determined in samples from 2 separate case-control studies with white individuals. The first study included healthy individuals (n = 310) and patients with ACD (n = 86). These patients were polysensitized as defined by a contact sensitization to para-substituted aryl compounds and at least one other structurally unrelated allergen. The second study comprised healthy subjects (n = 214) and patients with AD (n = 94). RESULTS:IL16 -295 genotypes were differently distributed among polysensitized and healthy control subjects (P =.0021). In particular, the IL16 -295*C/C genotype was overrepresented among polysensitized individuals (7.0% vs 1.0% in the control group; odds ratio, 7.68; 95% CI, 1.59-48.12). In contrast, there was no evidence for an association between the IL16 -295 polymorphism and AD. CONCLUSION: The IL16 -295 promoter polymorphism might influence susceptibility to contact allergy.
Authors: F Biagi; A Schiepatti; C Badulli; I Sbarsi; L Trotta; G E Feurle; C Müller; V Moos; T Schneider; T Marth; M De Amici; M Martinetti; G R Corazza Journal: Eur J Clin Microbiol Infect Dis Date: 2015-07-08 Impact factor: 3.267
Authors: Michelle Ma; Caroline M Percopo; Daniel E Sturdevant; Albert C Sek; Hirsh D Komarow; Helene F Rosenberg Journal: J Immunol Date: 2019-06-10 Impact factor: 5.422
Authors: M Folwaczny; J Glas; H-P Török; L Tonenchi; E Paschos; O Malachova; B Bauer; C Folwaczny Journal: Clin Exp Immunol Date: 2005-10 Impact factor: 4.330
Authors: M Peiser; T Tralau; J Heidler; A M Api; J H E Arts; D A Basketter; J English; T L Diepgen; R C Fuhlbrigge; A A Gaspari; J D Johansen; A T Karlberg; I Kimber; J P Lepoittevin; M Liebsch; H I Maibach; S F Martin; H F Merk; T Platzek; T Rustemeyer; A Schnuch; R J Vandebriel; I R White; A Luch Journal: Cell Mol Life Sci Date: 2011-10-14 Impact factor: 9.261
Authors: Jochen Brasch; Detlef Becker; Werner Aberer; Andreas Bircher; Birger Kränke; Kirsten Jung; Bernhard Przybilla; Tilo Biedermann; Thomas Werfel; Swen Malte John; Peter Elsner; Thomas Diepgen; Axel Trautmann; Hans F Merk; Thomas Fuchs; Axel Schnuch Journal: Allergo J Int Date: 2014
Authors: Victor Hugo de Souza; Josiane Bazzo de Alencar; Bruna Tiaki Tiyo; Hugo Vicentin Alves; Evelyn Castillo Lima Vendramini; Ana Maria Sell; Jeane Eliete Laguila Visentainer Journal: Oncotarget Date: 2020-09-08